Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires.

Journal of clinical medicine·2022

Same author

ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours.

Journal of neuroendocrinology·2021

Same author

Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).

Annals of surgical oncology·2021

Same author

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.

Neuroendocrinology·2021

Same author

Cardiac Imaging in Carcinoid Heart Disease.

JACC. Cardiovascular imaging·2021

Same author

Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series.

Asia-Pacific journal of clinical oncology·2021

Search research articles

Related Experiment Video

Updated: May 12, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Biotherapies for GEP-NETs.

¹Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden. kjell.oberg@medsci.uu.se

Best Practice & Research. Clinical Gastroenterology

|April 16, 2013

Summary

This summary is machine-generated.

Somatostatin analogues and alpha interferons are key biological treatments for gastrointestinal neuroendocrine tumors (GI NETs). These therapies offer symptomatic and biochemical improvements, with some patients experiencing tumor shrinkage.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Related Experiment Videos

Last Updated: May 12, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Area of Science:

Oncology
Gastroenterology
Endocrinology

Background:

Biological treatments for GI neuroendocrine tumors (NETs) primarily involve somatostatin analogues and alpha interferons.
These therapies were initially developed in the 1980s for carcinoid syndrome in small intestinal NETs.
Tumor biology studies revealed benefits for well-differentiated NETs (G1-tumors).

Purpose of the Study:

To review the role of somatostatin analogues and alpha interferons in managing GI neuroendocrine tumors.
To assess the efficacy of these biological agents in terms of symptomatic, biochemical, and tumor shrinkage responses.
To evaluate the potential of combination therapy and application in different NET grades.

Main Methods:

Review of biological treatments for GI neuroendocrine tumors.
Analysis of efficacy data for somatostatin analogues and alpha interferons.
Consideration of tumor differentiation (G1, G2) and proliferation in treatment strategies.

Main Results:

Somatostatin analogues and alpha interferons provide symptomatic improvement in 40-60% of patients with functioning tumors.
Biochemical responses are observed in 50-70% of patients.
Significant tumor shrinkage occurs in 5-10% of patients, with combination therapy showing some clinical benefit.

Conclusions:

Somatostatin analogues and alpha interferons remain important first-line treatments for functioning and non-functioning well-differentiated NETs (G1-tumors).
Somatostatin analogues may also be used to manage clinical symptoms in G2-tumors with higher proliferation.